Study examines brain scans of COVID-19 patients

In a Journal of Neuroimaging analysis of data obtained from 193 patients with COVID-19 who had brain and/or spine imaging and a lumbar puncture because of neurologic symptoms, investigators found that imaging results were related to the presence of SARS-CoV-2 in the cerebrospinal fluid.

The results were called central nervous system hyperintense lesions and leptomeningeal enhancement. Ten percent of patients with hyperintense lesions in the brain/spine had a positive PCR test result for SARS-CoV-2 in the cerebrospinal fluid, compared with no patients without hyperintense lesions in the brain/spine.

Twenty-five percent of patients with leptomeningeal enhancement had a positive PCR test result for SARS-CoV-2 in the cerebrospinal fluid, compared with 5% of patients without leptomeningeal enhancement.

Understanding the relationship between imaging and cerebrospinal fluid findings can improve understanding of neurological symptoms in patients with COVID-19. Although hyperintense lesions in the brain/spine and leptomeningeal enhancement are associated with the presence of SARS-CoV-2 in the cerebrospinal fluid, it is important to recognize that a positive SARS-CoV-2 PCR in the cerebrospinal fluid is uncommon."

Ariane Lewis, MD, Study Lead Author, NYU Langone Medical Center

"These imaging findings are predominantly the result of inflammation, hypoxia, or ischemia, rather than infection, of the central nervous system," said lead author Ariane Lewis, MD, of NYU Langone Medical Center.

Source:
Journal reference:

Lewis, A., et al. (2021) COVID-19 associated brain/spinal cord lesions and leptomeningeal enhancement: A meta-analysis of the relationship to CSF SARS-CoV-2. Journal of Neuroimaging.  
doi.org/10.1111/jon.12880.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
£1M funding boost for new project to trial Parkinson’s treatments on digital twin brain